Effect of remimazolam vs propofol in high-risk patients undergoing upper gastrointestinal endoscopy: a non-inferiority randomized controlled trial
DiscussionThis trial aims to determine whether remimazolam is non-inferior to propofol for procedural sedation during upper gastrointestinal endoscopy in high-risk patients, regarding success rate, complication incidence, patient comfort, and satisfaction.Trial registration {2a and 2b}Chinese Clinical Trial Registry ClinicalTrials.gov ChiCTR2200066527. Registered on 7 December 2022.
Source: Trials - Category: Research Source Type: clinical trials
More News: China Health | Clinical Trials | Diprivan | Endoscopy | Gastroenterology | Propofol | Research | Respiratory Medicine | Study | Upper Endoscopy